Large-scale data integration for systems- level understanding of - PowerPoint PPT Presentation

Jul 25, 2020 •286 likes •555 views

Large-scale data integration for systems- level understanding of complex diseases How do GWAS, NexGen sequencing, microRNAs and -OMICs relate? Sergio E. Baranzini, PhD Associate Professor, Department of Neurology University of

Large-scale data integration for systems- level understanding of complex diseases How do GWAS, NexGen sequencing, microRNAs and ‘-OMICs’ relate? Sergio E. Baranzini, PhD Associate Professor, Department of Neurology University of California, San Francisco B2PM Vancouver, BC March 8-9, 2011
Physiological/pathological Process (health/disease) neurodegenerative metabolic autoimmunity cancer infectious Cell cycle apoptosis Cellular process Cell differentiation pathways proteins expression genomic
The complex disease paradox • >80 susceptibility variants found to date • <25% heritability explained
CD4 + T Lymphocytes Twins 041896 Twins 230178 Twins 041907 Affected Unaffected Affected Unaffected Affected Unaffected Reads (x10 9 ) >1 >1 n.d. n.d. n.d. n.d. Coverage (X) 21.7 22.5 n.d. n.d. n.d. n.d. Coverage of Reference (%) 99.6 99.5 n.d. n.d. n.d. n.d. Number of SNPs (x10 6 ) 3.55 3.66 n.d. n.d. n.d. n.d. SNP differences / total 3,241 / 1,089,550 n.d. n.d. n.d. n.d. DNA Confirmed by Sanger Seq. 0 / 15 Number of indels (x10 6 ) 0.22 0.20 n.d. n.d. n.d. n.d. Indel differences / total 213 / 27,121 n.d. n.d. n.d. n.d. SNP differences / total 126 / 736,908 153 / 783,342 120 / 796,990 CNV differences / total 0 / 143 0 / 13 0 / 58 Number of CpG sites 2,146,620 2,033,078 1,636,285 1,917,131 1,779,140 1,642,200 CpG differences 2 10 176 mRNA reads (x10 6 ) 50/63 51/62 63 68 65 57 Number of differentially 13,714 / 28,443 8,595 / 28,443 14,163 / 28,443 expressed genes / total cSNP differences / total 322 / 51,523 1,017 / 40,833 380 / 18,503 RNA Differential allelic expression 115 n.d. n.d. Number of differentially 1,721 / 22,877 n.d. n.d. expressed genes / total
Coverage GS1641 GS1679 GS1685 GS1687 GS1748 GS1768 GS1843 GS1881 GS1883 GS1884 GS1901 GS1922 GS2023 10X 0.963 0.960 0.966 0.960 0.963 0.966 0.963 0.967 0.965 0.961 0.966 0.968 0.963 20X 0.938 0.927 0.940 0.928 0.937 0.943 0.936 0.947 0.938 0.931 0.946 0.947 0.930 30X 0.897 0.872 0.898 0.874 0.896 0.905 0.892 0.918 0.892 0.884 0.915 0.916 0.870 40X 0.836 0.790 0.830 0.794 0.836 0.845 0.827 0.875 0.818 0.816 0.868 0.867 0.772 50X 0.756 0.685 0.737 0.693 0.756 0.760 0.742 0.817 0.716 0.730 0.805 0.800 0.640 60X 0.659 0.565 0.623 0.577 0.660 0.653 0.641 0.746 0.593 0.632 0.728 0.716 0.491 100X 0.242 0.145 0.184 0.165 0.252 0.213 0.233 0.395 0.157 0.247 0.355 0.318 0.085

Recommend

Nails Examination and Disorders Samantha Eisman Dermatologist MBChB/ MRCP/ FCDerm(SA)/ FACD

15/09/2016 Nails Examination and Disorders Samantha Eisman Dermatologist MBChB/ MRCP/ FCDerm(SA)/ FACD Overview Demystify nails QUIZ Talk Examination nails and and site specific disease QUIZ answers and cover common nails

491 views • 20 slides

27th January 31 st January Facial Hair Transplant The Beard Mr

27th January 31 st January Facial Hair Transplant The Beard Mr Michael W. May FRCS The Wimpole Clinic Introduction Beards are in fashion Some clinics are performing 3-4 beard hair transplants per month

1.2k views • 21 slides

Sickle Cell Treatment: Pain, Opioids, Hydroxyurea, and More James G. Taylor VI, M.D. Professor

#CureSickleCellNow Sickle Cell Treatment: Pain, Opioids, Hydroxyurea, and More James G. Taylor VI, M.D. Professor , Department of Medicine Director, Howard University Center for Sickle Cell Disease October 31, 2017 41st Annual Eastern

843 views • 68 slides

14/06/2018 LEARNING OBJECTIVES HOW TO MAKE THE PATIENT 1. Understand the features of common

14/06/2018 LEARNING OBJECTIVES HOW TO MAKE THE PATIENT 1. Understand the features of common primary and secondary headache disorders that may present WITH HEADACHE NOT A to optometrists 2. Employ an appropriate mix of open and closed

393 views • 4 slides

Neuropathic Pain Hands, Feet and Heart - Neuropathy Support Group for Central Texans February

Neuropathic Pain Hands, Feet and Heart - Neuropathy Support Group for Central Texans February 12th, 2011 Mihnea Dumitrescu, M.D. Precision Pain Consultants www.austinppc.com Pain Sufferers in the U.S. P O P U L A T I O N Pain

964 views • 60 slides

First Name Last Name Organization Paper Title Poster Number Presentation Date Theme HOW CAN I

First Name Last Name Organization Paper Title Poster Number Presentation Date Theme HOW CAN I USE ONLINE TOOLS IN MY TEACHING OF 1. History of neuroscience and Femke Buisman-Pijlman University of Adelaide NEUROSCIENCE COURSES? 1

424 views • 24 slides

AOPT 10 th Scientific Meeting February 17 20, 2011 Fort Worth, Texas AGENDA THURSDAY,

AOPT 10 th Scientific Meeting February 17 20, 2011 Fort Worth, Texas AGENDA THURSDAY, FEBRUARY 17 th 5:00 7:00 PM Registration & Welcome Reception FRIDAY, FEBRUARY 18 th 7:00 9:00 AM Shuttle Available from the Courtyard

73 views • 5 slides

Assessment, diagnosis and management of leg ulcers Sarah Gardner, Clinical lead, Tissue viability

Assessment, diagnosis and management of leg ulcers Sarah Gardner, Clinical lead, Tissue viability service Aim of the session T o develop a better understanding of the factors that contribute to the development of leg ulceration and how the

1.11k views • 82 slides

Oral Presentation C0de Acceptance Time / Date Title Author - 94/02/23 -

Oral Presentation C0de Acceptance Time / Date Title Author - 94/02/23 - Gabapentin effects on sedation and pain in patients 7 Oral Bahador Bagheri 9:45 - 8:00 - receiving tetracaine -

178 views • 6 slides

Sarah Nockengost Virginia Commonwealth University Childrens Hospital

Sarah Nockengost Virginia Commonwealth University Childrens Hospital of Richmond at VCU Objec&ves Define three chronic conditions commonly seen in

473 views • 31 slides

Entrepreneurship Bootcamp Session 2 - Project, Product or Company Mark A. Tepper, Ph.D.

1 1 Entrepreneurship Bootcamp Session 2 - Project, Product or Company Mark A. Tepper, Ph.D. President & CSO Corbus Pharmaceuticals Inc. June 3, 2018 Developing Medicines which modulate the endocannabinoid system JB Therapeutics:

498 views • 20 slides

Dr. Christopher Jenner MB BS, FRCA, FFPMRCA Consultant in Pain Medicine, Charing Cross Hospital

Dr. Christopher Jenner MB BS, FRCA, FFPMRCA Consultant in Pain Medicine, Charing Cross Hospital Imperial Healthcare NHS Trust Honorary Lecturer, Imperial Clinical Director, The London Pain Clinic Chronic Pain in the Medico Legal Context 19

446 views • 41 slides

Ra Medical Systems, Inc. NYSE: RMED Corporate Presentation May 2019 Disclaimer Certain

Ra Medical Systems, Inc. NYSE: RMED Corporate Presentation May 2019 Disclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future

635 views • 27 slides

DERMATOLOGIST, MOHS SURGEON CHUGLD, MONCTON NB Disclosures / Conflicts of interest

DR MARTIN LEBLANC MD FRCPC FCDA DERMATOLOGIST, MOHS SURGEON CHUGLD, MONCTON NB Disclosures / Conflicts of interest Honorariums : AbbVie Sanofi-Genzyme Canada LEO Objectives : Overview of the cutaneous adverse effects of

909 views • 28 slides

Poster Session 1A , HALL'B' , FTK CIT Hall Chairman Dr B D Khan Co Chairman Dr Umar Jahangir

Poster Session 1A , HALL'B' , FTK CIT Hall Chairman Dr B D Khan Co Chairman Dr Umar Jahangir Rapoteaur Dr Zeba Afrin APPROACHES CONSIDERATION IN THE MANAGEMENT OF HYPERTENSION (ZAGHTUDDAM QAWI) BY MEANS OF CL05 FARZANA KHATOON

107 views • 6 slides

Dermatitis herpetiformis Part I. Epidemiology, pathogenesis, and clinical presentation Diana

C ONTINUING MEDICAL EDUCATION Dermatitis herpetiformis Part I. Epidemiology, pathogenesis, and clinical presentation Diana Bolotin, MD, PhD, and Vesna Petronic-Rosic, MD, MSc Chicago, Illinois Dermatitis herpetiformis (DH) is an autoimmune

302 views • 8 slides

for Patient-Centered Outcomes Research AcademyHealth 2018 Annual Research Meeting June 25, 2018

Sustaining Partnerships for Patient-Centered Outcomes Research AcademyHealth 2018 Annual Research Meeting June 25, 2018 Welcome & Introductions Kristin L. Carman, PhD Courtney Clyatt, MA, MPH Lia Hotchkiss, MPH Julie K. Lesch, MPA

728 views • 50 slides

Unproven cell-based therapies: a risk to public health and to the development of advanced

Unproven cell-based therapies: a risk to public health and to the development of advanced therapies Dr Kieran Breen Committee for Advanced Therapies An agency of the European Union Cell-based therapies Cell- based medicinal products have the

378 views • 11 slides

Development of viva voce exam to assess clinical reasoning in the paraclinical phase of a BVSc

Development of viva voce exam to assess clinical reasoning in the paraclinical phase of a BVSc program. Helen Owen, Senior Lecturer in Veterinary Pathology and Jus:ne Gibson, Senior Lecturer in Veterinary Bacteriology and Mycology Dr Tamsin

497 views • 29 slides

SALT 20 was statistically significant from placebo for the 8 and 12 mg BID cohorts in alopecia

Abstract: American Academy of Dermatology Annual Meeting 2020 New CTP-543 (Oral JAK1/2 Inhibitor) Phase 2 Analyses: SALT 20 was statistically significant from placebo for the 8 and 12 mg BID cohorts in alopecia areata trial James Cassella, PhD;

318 views • 16 slides

Wegener s Granulomatosis An unusual Presentation Article in Indian Journal of Dermatology

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/45263160 Wegener s Granulomatosis An unusual Presentation Article in Indian Journal of Dermatology January 2000 Source: DOAJ

398 views • 17 slides

Detail of Poster / Paper Presentation GEETANJALI MEDICAL COLLEGE & HOSPITAL S. No. Name of

GEETANJALI UNIVERSITY Detail of Poster / Paper Presentation GEETANJALI MEDICAL COLLEGE & HOSPITAL S. No. Name of Faculty Department Topic Presented At 1 Dr. Animesh Gaur General Medicine A rare case of pulmonary tuberculosis. Joint

3.2k views • 6 slides

RADY 401 Case Presentation Ed. John Lilly, MD 69 yo male with PMH Benign Prostatic Hypertrophy

RADY 401 Case Presentation Ed. John Lilly, MD 69 yo male with PMH Benign Prostatic Hypertrophy (BPH), HTN, DM, coronary angioplasty, and 1 year hx of urinary retention presents for prostate artery embolization (PAE) T 97.7F, BP 142/80, HR

444 views • 26 slides

Michael Bhm, MD on behalf of the GSR Investigators March 30, 2014 Universittskliniken des

The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension Michael Bhm, MD on behalf of the GSR Investigators March 30, 2014 Universittskliniken des

409 views • 26 slides